Literature DB >> 7665039

Benzodiazepine prescribing in general practice: dispelling some myths.

A Mant1, R P Mattick, S de Burgh, N Donnelly, W Hall.   

Abstract

The objective was to analyse clinical and non-clinical factors associated with the receipt of a prescription for a benzodiazepine among general practice patients. A survey of 110 consecutive patient encounters (consultations) as recorded by a representative sample of general practitioners in inner urban, outer urban and rural settings was designed. A total of 286 general practitioners took part during 1991-2. 31,256 patients (10,683 male; 34%) were surveyed and the odds of receiving a benzodiazepine script measured. Insomnia, unlike anxiety, was almost routinely managed with a benzodiazepine alone (insomnia 89.6%; anxiety 49.4%), whereas anxiety was more likely to be managed with non-drug management (insomnia 7.2%; anxiety 38.3%). In multiple logistic regression, the variables significantly associated with the prescription of a benzodiazepine included being a female patient, being an older patient and being an established patient, who attends a GP working in a busy practice in an inner urban area. A second regression model was run with the addition of three variables, namely the presenting problems of anxiety and insomnia, and the number of health problems. The only predictors of benzodiazepine prescribing in the full model were these three clinical variables together with patient age. There is a need to educate doctors about the non-drug management of insomnia. The stereotype of the doctor over-prescribing a benzodiazepine without an appropriate problem/diagnosis should be questioned. On the other hand, there is concern that patient age continues to be associated with a prescription of these medications, when all other clinical and non-clinical factors are taken into account.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7665039     DOI: 10.1093/fampra/12.1.37

Source DB:  PubMed          Journal:  Fam Pract        ISSN: 0263-2136            Impact factor:   2.267


  8 in total

1.  Initial benzodiazepine use and improved health-related quality of life.

Authors:  Rolf van Hulten; Bart Teeuw; Albert Bakker; Hubert G Leufkens
Journal:  Pharm World Sci       Date:  2005-02

2.  Variations in anxiolytic and hypnotic prescribing by GPs: a cross-sectional analysis using data from the UK Quality and Outcomes Framework.

Authors:  Zoi Tsimtsiou; Mark Ashworth; Roger Jones
Journal:  Br J Gen Pract       Date:  2009-06       Impact factor: 5.386

3.  [Factors that affect the prescription of benzodiazepines and actions to improve their use: a Delphi study of primary care doctors].

Authors:  T Fernández Alvarez; M J Gómez Castro; C Baides Morente; J Martínez Fernández
Journal:  Aten Primaria       Date:  2002-09-30       Impact factor: 1.137

4.  Correlates of (inappropriate) benzodiazepine use: the Netherlands Study of Depression and Anxiety (NESDA).

Authors:  Leonie Manthey; Tineke van Veen; Erik J Giltay; José E Stoop; Arie Knuistingh Neven; Brenda W J H Penninx; Frans G Zitman
Journal:  Br J Clin Pharmacol       Date:  2011-02       Impact factor: 4.335

5.  Initial 3-month usage characteristics predict long-term use of benzodiazepines: an 8-year follow-up.

Authors:  Rolf van Hulten; K Bart Teeuw; Albert Bakker; Hubert G Leufkens
Journal:  Eur J Clin Pharmacol       Date:  2003-02-07       Impact factor: 2.953

6.  The lesser evil? Initiating a benzodiazepine prescription in general practice: a qualitative study on GPs' perspectives.

Authors:  Sibyl Anthierens; Hilde Habraken; Mirko Petrovic; Thierry Christiaens
Journal:  Scand J Prim Health Care       Date:  2007-12       Impact factor: 2.581

7.  Gaining insight into benzodiazepine prescribing in General Practice in France: a data-based study.

Authors:  Sophia Rosman; Marc Le Vaillant; Nathalie Pelletier-Fleury
Journal:  BMC Fam Pract       Date:  2011-05-11       Impact factor: 2.497

Review 8.  General practitioners' experiences and perceptions of benzodiazepine prescribing: systematic review and meta-synthesis.

Authors:  Coral Sirdifield; Sibyl Anthierens; Hanne Creupelandt; Susan Y Chipchase; Thierry Christiaens; Aloysius Niroshan Siriwardena
Journal:  BMC Fam Pract       Date:  2013-12-13       Impact factor: 2.497

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.